SILENCE THERAPEUTICS ORD 5P news, videos and press releases - Page 2
For more news please use our advanced search feature.
SILENCE THERAPEUTICS ORD 5P - More news...
SILENCE THERAPEUTICS ORD 5P - More news...
- Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
- Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
- Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
- Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
- Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
- Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
- Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
- Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
- New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
- Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
- Silence Therapeutics Begins Exclusive Nasdaq Trading
- Silence Therapeutics to Present at Jefferies London Healthcare Conference
- Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
- Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
- Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
- Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
- Silence Therapeutics to Host R&D Day on October 21, 2021
- Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
- Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
- Silence Therapeutics to Participate in September Investor Conferences
- Silence Therapeutics Reports Half-Year 2021 Results
- Notice of half year results
- Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
- Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
- Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference
- Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness
- Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases
- Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
- Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference